图片来源: JD.com product page
枸地氯雷他定片
Beixue (Desloratadine Citrate Disodium Tablets)
| 生产企业 | 扬子江药业集团 (Yangtze River Pharmaceutical Group) |
|---|---|
| 剂型 | Film-coated tablets |
| 类别 | [西药] |
适应症 / Indications
Chronic idiopathic urticaria (hives) and perennial allergic rhinitis (year-round nasal allergies).
产品说明 / Description
A salt form of desloratadine, a second-generation antihistamine. Effectively equivalent to desloratadine base. Non-sedating at standard doses. Well-studied in large Phase III trials with thousands of patients.
成分 / Ingredients
Desloratadine citrate disodium 8.8 mg per tablet (equivalent to desloratadine 5 mg).
◆ 临床证据 / Clinical Evidence
Desloratadine is supported by extensive Phase III clinical trials involving thousands of patients. It significantly reduces symptoms of chronic urticaria and allergic rhinitis compared to placebo. Non-sedating at the recommended dose. The citrate disodium salt form (Beixue) was approved based on bioequivalence to the reference desloratadine.
| 研究类型 | 文献来源 | 主要发现 |
|---|---|---|
| Phase III RCTs | Multiple trials, FDA/EMA filings | Significant symptom reduction in chronic urticaria and allergic rhinitis vs placebo |
